These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 37189604)

  • 61. The pathologic basis of recovery.
    Narula N; Agozzino M; Gazzoli F; Concardi M; Pagani F; Favalli V; Kodama T; Mazzola A; D'Armini AM; Arbustini E
    Heart Fail Clin; 2014 Jan; 10(1 Suppl):S63-74. PubMed ID: 24262354
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Morphological and molecular changes of the myocardium after left ventricular mechanical support.
    Baba HA; Wohlschlaeger J
    Curr Cardiol Rev; 2008 Aug; 4(3):157-69. PubMed ID: 19936192
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Echocardiographic predictors of reverse remodeling after cardiac resynchronization therapy and subsequent events.
    Park JH; Negishi K; Grimm RA; Popovic Z; Stanton T; Wilkoff BL; Marwick TH
    Circ Cardiovasc Imaging; 2013 Nov; 6(6):864-72. PubMed ID: 24084489
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Left ventricular assist device-induced molecular changes in the failing myocardium.
    Soppa GK; Barton PJ; Terracciano CM; Yacoub MH
    Curr Opin Cardiol; 2008 May; 23(3):206-18. PubMed ID: 18382208
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Myocardial recovery in peri-partum cardiomyopathy after continuous flow left ventricular assist device.
    Lund LH; Grinnemo KH; Svenarud P; van der Linden J; Eriksson MJ
    J Cardiothorac Surg; 2011 Nov; 6():150. PubMed ID: 22082339
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The impact of angiotensin-converting enzyme inhibitor therapy on the extracellular collagen matrix during left ventricular assist device support in patients with end-stage heart failure.
    Klotz S; Danser AH; Foronjy RF; Oz MC; Wang J; Mancini D; D'Armiento J; Burkhoff D
    J Am Coll Cardiol; 2007 Mar; 49(11):1166-74. PubMed ID: 17367660
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Effect of Cardiac Resynchronization Therapy on Myocardial Fibrosis and Relevant Cytokines in a Canine Model With Experimental Heart Failure.
    Wang J; Gong X; Chen H; Qin S; Zhou N; Su Y; Ge J
    J Cardiovasc Electrophysiol; 2017 Apr; 28(4):438-445. PubMed ID: 28127817
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Left Ventricular Hemodynamics and Relationship With Myocardial Recovery and Optimization in Patients Supported on CF-LVAD Therapy.
    Rosenbaum AN; Geske JB; Stulak JM; Kushwaha SS; Clavell AL; Behfar A
    J Card Fail; 2022 May; 28(5):799-806. PubMed ID: 34929296
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Left ventricular markers of mortality and ventricular arrhythmias in heart failure patients with cardiac resynchronization therapy.
    Hasselberg NE; Haugaa KH; Bernard A; Ribe MP; Kongsgaard E; Donal E; Edvardsen T
    Eur Heart J Cardiovasc Imaging; 2016 Mar; 17(3):343-50. PubMed ID: 26164406
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Exercise Tolerance in Patients Treated With a Durable Left Ventricular Assist Device: Importance of Myocardial Recovery.
    Dridi NP; Vishram-Nielsen JKK; Gustafsson F
    J Card Fail; 2021 Apr; 27(4):486-493. PubMed ID: 33347995
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Cardiac Resynchronization Therapy in continuous flow Left Ventricular Assist Device Recipients: A Systematic Review and Meta-analysis from ELECTRAM Investigators.
    Shah K; Karpe V; K Turagam M; Shah M; Natale A; Gopinathannair R; Lakkireddy D; Garg J
    J Atr Fibrillation; 2020 Dec; 13(4):2441. PubMed ID: 34950326
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Effect of Continuous-Flow Mechanical Circulatory Support on Microvasculature Remodeling in the Failing Heart.
    Saito T; Miyagawa S; Toda K; Yoshikawa Y; Fukushima S; Saito S; Yoshioka D; Sakata Y; Daimon T; Sawa Y
    Artif Organs; 2019 Apr; 43(4):350-362. PubMed ID: 30129970
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Cardiac resynchronization therapy restored ventricular septal myocardial perfusion and enhanced ventricular remodeling in patients with nonischemic cardiomyopathy presenting with left bundle branch block.
    Ogano M; Iwasaki YK; Tanabe J; Takagi H; Umemoto T; Hayashi M; Miyauchi Y; Shimizu W
    Heart Rhythm; 2014 May; 11(5):836-41. PubMed ID: 24561161
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Cardiac resynchronization therapy restores sympathovagal balance in the failing heart by differential remodeling of cholinergic signaling.
    DeMazumder D; Kass DA; O'Rourke B; Tomaselli GF
    Circ Res; 2015 May; 116(10):1691-9. PubMed ID: 25733594
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Comparison of left ventricular reverse remodeling induced by cardiac contractility modulation and cardiac resynchronization therapy in heart failure patients with different QRS durations.
    Zhang Q; Chan YS; Liang YJ; Fang F; Lam YY; Chan CP; Lee AP; Chan KC; Wu EB; Yu CM
    Int J Cardiol; 2013 Aug; 167(3):889-93. PubMed ID: 22330007
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Percutaneous approach to left ventricular assist device decommissioning.
    Moroni F; Shah KB; Quader MA; Klein K; Smallfield MC; Parris KE; Gertz ZM
    Catheter Cardiovasc Interv; 2022 Jul; 100(1):169-174. PubMed ID: 35579199
    [TBL] [Abstract][Full Text] [Related]  

  • 77. A blood assist index control by intraaorta pump: a control strategy for ventricular recovery.
    Gao B; Gu K; Zeng Y; Liu Y; Chang Y
    ASAIO J; 2011; 57(5):358-62. PubMed ID: 21734559
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Left ventricular assist device support normalizes left and right ventricular beta-adrenergic pathway properties.
    Klotz S; Barbone A; Reiken S; Holmes JW; Naka Y; Oz MC; Marks AR; Burkhoff D
    J Am Coll Cardiol; 2005 Mar; 45(5):668-76. PubMed ID: 15734609
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Pathological findings in cardiac apex removed during implantation of left ventricular assist devices (LVAD) are non-specific: 13-year-experience at a German Heart Center.
    Strecker T; Rösch J; Weyand M; Agaimy A
    Int J Clin Exp Pathol; 2014; 7(9):5549-56. PubMed ID: 25337196
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Impact of paced left ventricular dyssynchrony on left ventricular reverse remodeling after cardiac resynchronization therapy.
    Gauthey A; Willemen E; Lumens J; Ploux S; Bordachar P; Ritter P; Prinzen FW; Lejeune S; Pouleur AC; Garnir Q; Marchandise S; Scavée C; Wauters A; le Polain de Waroux JB
    J Cardiovasc Electrophysiol; 2020 Feb; 31(2):494-502. PubMed ID: 31908084
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.